Smoking Cessation
Tobacco
Tobacco Use Disorder
Tobacco, Smokeless
Tobacco Industry
Smoking cessation with four nicotine replacement regimes in a lung clinic. (1/156)
Smoking cessation is a key intervention for prevention of several lung diseases. The aim of the present study was to compare the effect of smoking cessation with nicotine replacement in a lung clinic in a low resource set-up suitable for implementation in other lung clinics. This was an open, randomized trial with 4 different nicotine replacement regimes combined with minimal behavioural support in daily routine. A total of 446 smokers (>9 cigarettes x day(-1)) were allocated to a nurse-conducted smoking cessation programme with 4 treatment arms: a 5-mg nicotine patch ("placebo"), a 15-mg nicotine patch, nicotine inhaler, and a 15-mg nicotine patch plus nicotine inhaler. Recommended use of the nicotine products were 3 months with the possibility of continuing use up to 9 months on an individual basis. Individual follow-up studies were scheduled after 2 and 6 weeks, 3, 6, 9 and 12 months. The 12-month point prevalence was 6% (5-mg patch (placebo)), 16% (15-mg patch) (p<0.05), 9% (inhaler) and 11% (15-mg patch plus inhaler), respectively. To conclude, the set-up investigated in this study which included minimal behavioural support with nicotine patches should be evaluated in other lung clinics, as it doubled success rate when compared to a placebo with a 1-yr point prevalence of 16% and also the resources used are limited. (+info)Tobacco cessation, the dental profession, and the role of dental education. (2/156)
This article describes the development of a comprehensive, interdisciplinary, tobacco cessation program based on twenty years of experience at the Indiana University (IU) School of Dentistry. It reviews the relationship between tobacco use and oral health, the nature of nicotine addiction and cessation approaches involving nicotine replacement therapy. In the early 1980s, tobacco control curriculum and cessation guidelines were introduced at the IU School of Dentistry and cooperative efforts initiated with other U.S. and Canadian dental schools. During the past decade, an interdisciplinary Nicotine Dependence Program has been developed to serve outpatients receiving treatment at all hospitals on the IU Medical Center campus. It is hoped that the models described here will be of value to other dental schools developing educational curricula and tobacco control and cessation programs. (+info)Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. (3/156)
AIMS: Previously, we determined the phenotyping of in vivo nicotine metabolism and the genotyping of the CYP2A6 gene (CYP2A6*1 A, CYP2A6*1B, CYP2A6*2, CYP2A6*3, CYP2A6*4 and CYP2A6*5 ) in 92 Japanese and 209 Koreans. In the study, we found one Korean and four Japanese subjects genotyped as CYP2A6*1B/CYP2A6*4 who revealed impaired nicotine metabolism, although other many heterozygotes of CYP2A6*4 demonstrated normal nicotine metabolism (CYP2A6*4 is a whole deletion type). After our previous report, several CYP2A6 alleles, CYP2A6*6 (R128Q), CYP2A6*7 (I471T), and CYP2A6*8 (R485L), have been reported. The purpose of the present study was to clarify whether the impaired nicotine metabolism can be ascribed to these CYP2A6 alleles. Furthermore, we also determined whether the subjects possessing CYP2A6*1x2 (duplication) reveal higher nicotine metabolism. METHODS: Genotyping of CYP2A6 alleles, CYP2A6*6, CYP2A6*7, CYP2A6*8, and CYP2A6*1x2 was determined by PCR. RESULTS: The five poor metabolizers were re-genotyped as CYP2A6*7/CYP2A6*4, suggesting that a single nucleotide polymorphism (SNP) causing I471T decreases nicotine metabolism in vivo. Furthermore, we found that two subjects out of five with a lower potency of nicotine metabolism possessed SNPs of CYP2A6*7 and CYP2A6*8 simultaneously. The novel allele was termed CYP2A6*10. In the 92 Japanese and 209 Koreans, the CYP2A6*6 allele was not found. The allele frequencies of CYP2A6*7, CYP2A6*8, and CYP2A6*10 were 6.5%, 2.2%, and 1.1%, respectively, in Japanese, and 3.6%, 1.4%, and 0.5%, respectively, in Koreans. The CYP2A6*1x2 allele was found in only one Korean subject (0.5%) whose nicotine metabolic potency was not very high. CONCLUSIONS: It was clarified that the impaired in vivo nicotine metabolism was caused by CYP2A6*7 and CYP2A6*10 alleles. (+info)In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. (4/156)
The association between the distribution characteristics of CYP2A6 catalytic activities toward nicotine and coumarin, and the frequency distribution of CYP2A6 variant alleles reported was estimated in 120 healthy Thais. The distributions of the subjects as classified by the amounts of 7-hydroxycoumarin (7-OHC) excreted in the urine and by cotinine/nicotine ratio in the plasma were clearly bimodal. However, the numbers of apparently poor metabolizers for coumarin and nicotine were different. The inter-individual variability in the in vivo dispositions of coumarin and nicotine closely related to the CYP2A6 genetic polymorphism. There was a close correlation between the rate of 7-OHC excretion in the urine and cotinine/nicotine ratio in the plasma among subjects (R=0.92, p<0.001). The frequency of CYP2A6 allele found in the present study was: CYP2A6*1A=32% (95% CI, 22.1-39.4%), CYP2A6*1B=27% (95% CI, 19.4-33.5%), CYP2A6*9=20% (95% CI, 17.6-23.3%), CYP2A6*4=14% (95% CI, 9.6-17.8%), CYP2A6*7=5% (95% CI, 3.7-9.4%), CYP2A6*10=2% (95% CI, 0.8-5.1%). Subjects having CYP2A6*1A/*1B were found to have a higher rate of 7-OHC excretion, as well as a higher cotinine/nicotine ratio in the plasma compared with those of the other genotypes. In contrast, subjects with CYP2A6*4/*7 and CYP2A6*7/*7 almost lacked any cotinine formation, whereas urinary 7-OHC was still detectable. CYP2A6*9 allele clearly resulted in reduced enzyme activities. Despite the absence of the homozygote for CYP2A6*10 allele, the presence of CYP2A6*10 allele significantly decreased the enzyme activities. The results of the present study demonstrate that in vivo phenotyping of CYP2A6 using nicotine and coumarin are not metabolically equivalent. Nicotine is a better probe according to its specificity, while coumarin is still valuable to be used for a routine CYP2A6 phenotyping since the test employs a non-invasive method. (+info)A novel duplication type of CYP2A6 gene in African-American population. (5/156)
Human CYP2A6 is responsible for the metabolism of nicotine and its genetic polymorphisms affect smoking behavior and risk of lung cancer. In the present study, we identified a novel type of CYP2A6 gene duplication that is created through an unequal crossover event with the CYP2A7 gene at 5.2 to 5.6 kilobases downstream from the stop codon. The novel duplication type of CYP2A6 was found in African Americans (n = 176) at an allele frequency of 1.7%, but was not found in European-American (n = 187), Korean (n = 209), or Japanese (n = 184) populations. The plasma cotinine/nicotine ratio in subjects possessing the novel CYP2A6 gene duplication with the CYP2A6*1 allele (10.8 +/- 7.0, n = 4) was 1.4-fold higher than that in homozygotes of the wild type (8.0 +/- 5.0, n = 87), although the difference was not statistically significant. The findings in the present study suggested that the novel duplicated CYP2A6 allele, which is specific for African Americans, would increase nicotine metabolism and may affect smoking behavior. (+info)Predictors of early abstinence in smokers with schizophrenia. (6/156)
(+info)A randomized clinical trial of nicotine lozenge for smokeless tobacco use. (7/156)
(+info)Effects of smoking cessation on body composition in postmenopausal women. (8/156)
(+info)Tobacco use cessation is the process of discontinuing the use of tobacco products, such as cigarettes, cigars, smokeless tobacco, and electronic cigarettes. This is often a critical component of treatment for tobacco-related diseases and conditions, as well as a key strategy for preventing tobacco-related illnesses and premature death.
The World Health Organization (WHO) recommends a combination of behavioral support and medication as the most effective approach to tobacco use cessation. Behavioral support may include counseling, group therapy, and self-help materials, while medication can include nicotine replacement therapies (such as gum, lozenges, patches, inhalers, or nasal sprays), as well as prescription medications such as bupropion and varenicline.
Tobacco use cessation is a challenging process that often requires multiple attempts before successful long-term abstinence is achieved. However, with the right support and resources, many tobacco users are able to quit successfully and improve their health outcomes.
Tobacco use cessation products are a type of pharmacological or nicotine replacement therapy (NRT) designed to help individuals stop using tobacco products, such as cigarettes, cigars, and smokeless tobacco. These products include:
1. Nicotine gum: A chewing gum that delivers nicotine to the body through the lining of the mouth.
2. Nicotine lozenges: Similar to nicotine gum, but in the form of a small tablet that dissolves slowly in the mouth.
3. Nicotine patch: A transdermal patch that delivers a steady dose of nicotine through the skin.
4. Nicotine inhaler: A device that looks like a cigarette and delivers nicotine vapor to be inhaled.
5. Nicotine nasal spray: A spray that delivers nicotine through the nostrils.
6. Non-nicotine prescription medications: Such as bupropion (Zyban) and varenicline (Chantix), which help reduce cravings and withdrawal symptoms.
These products are intended to help manage nicotine dependence and make it easier for individuals to quit tobacco use by alleviating the unpleasant symptoms of withdrawal. It is important to note that these products should be used as part of a comprehensive cessation plan, which may also include counseling and behavioral support.
Smoking cessation is the process of discontinuing tobacco smoking. This can be achieved through various methods such as behavioral modifications, counseling, and medication. The goal of smoking cessation is to improve overall health, reduce the risk of tobacco-related diseases, and enhance quality of life. It is a significant step towards preventing lung cancer, heart disease, stroke, chronic obstructive pulmonary disease (COPD), and other serious health conditions.
Tobacco is not a medical term, but it refers to the leaves of the plant Nicotiana tabacum that are dried and fermented before being used in a variety of ways. Medically speaking, tobacco is often referred to in the context of its health effects. According to the World Health Organization (WHO), "tobacco" can also refer to any product prepared from the leaf of the tobacco plant for smoking, sucking, chewing or snuffing.
Tobacco use is a major risk factor for a number of diseases, including cancer, heart disease, stroke, lung disease, and various other medical conditions. The smoke produced by burning tobacco contains thousands of chemicals, many of which are toxic and can cause serious health problems. Nicotine, one of the primary active constituents in tobacco, is highly addictive and can lead to dependence.
Tobacco Use Disorder is a clinical diagnosis described in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), used by healthcare professionals to diagnose mental health conditions. It is defined as a problematic pattern of tobacco use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period:
1. Tobacco is often taken in larger amounts or over a longer period than was intended.
2. There is a persistent desire or unsuccessful efforts to cut down or control tobacco use.
3. A great deal of time is spent on activities necessary to obtain or use tobacco, or recover from its effects.
4. Craving, or a strong desire or urge to use tobacco, occurs.
5. Recurrent tobacco use results in a failure to fulfill major role obligations at work, school, or home.
6. Important social, occupational, or recreational activities are given up or reduced because of tobacco use.
7. Tobacco use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by tobacco.
8. Tolerance, as defined by either of the following:
a. A need for markedly increased amounts of tobacco to achieve intoxication or desired effect.
b. Markedly diminished effect with continued use of the same amount of tobacco.
9. Characteristic withdrawal syndrome for tobacco, or tobacco is taken to relieve or avoid withdrawal symptoms.
The diagnosis excludes nicotine withdrawal that is a normal response to the cessation of tobacco use, intoxication, or substance/medication-induced disorders. Tobacco Use Disorder can be further specified as mild, moderate, or severe based on the number of criteria met.
Smokeless tobacco is a type of tobacco that is not burned or smoked. It's often called "spit" or "chewing" tobacco. The most common forms of smokeless tobacco in the United States are snuff and chewing tobacco. Snuff is a finely ground tobacco that can be dry or moist. Dry snuff is sniffed or taken through the nose, while moist snuff is placed between the lower lip or cheek and gum. Chewing tobacco is plugs, leaves, or twists of tobacco that are chewed or sucked on.
Smokeless tobacco contains nicotine, which is addictive. When you use smokeless tobacco, the nicotine is absorbed through the lining of your mouth and goes directly into your bloodstream. This can lead to a rapid increase in nicotine levels in your body, which can make it harder to quit using tobacco.
Smokeless tobacco also contains harmful chemicals that can cause cancer of the mouth, esophagus, and pancreas. It can also cause other health problems, such as gum disease, tooth decay, and precancerous lesions in the mouth. Using smokeless tobacco can also increase your risk of developing heart disease and having a stroke.
Tobacco use is the act of consuming or ingesting tobacco products, such as cigarettes, cigars, pipes, chewing tobacco, and snuff. The primary active chemical in tobacco is nicotine, which is highly addictive and can have serious health consequences.
When tobacco is smoked, nicotine is rapidly absorbed into the bloodstream and travels to the brain, where it activates the release of neurotransmitters like dopamine, leading to feelings of pleasure and relaxation. However, smoking also exposes the user to a range of harmful chemicals and toxins that can cause serious health problems, including cancer, heart disease, lung disease, and stroke.
Chewing tobacco and snuff can also lead to nicotine addiction and are associated with an increased risk of oral cancer, gum disease, and other health issues. Overall, tobacco use is a major public health concern and is responsible for millions of preventable deaths each year worldwide.
A Tobacco Industry is a commercial sector involved in the cultivation, production, manufacturing, marketing, and distribution of tobacco and tobacco-related products. This can include growers who produce tobacco leaves, manufacturers who process the leaves into various forms (such as cigarettes, chewing tobacco, or snuff), and companies that market and distribute these products to consumers. It is important to note that the tobacco industry has been associated with significant health risks, as the use of tobacco products can lead to a range of serious health problems, including cancer, heart disease, and lung disease.
Smoking is not a medical condition, but it's a significant health risk behavior. Here is the definition from a public health perspective:
Smoking is the act of inhaling and exhaling the smoke of burning tobacco that is commonly consumed through cigarettes, pipes, and cigars. The smoke contains over 7,000 chemicals, including nicotine, tar, carbon monoxide, and numerous toxic and carcinogenic substances. These toxins contribute to a wide range of diseases and health conditions, such as lung cancer, heart disease, stroke, chronic obstructive pulmonary disease (COPD), and various other cancers, as well as adverse reproductive outcomes and negative impacts on the developing fetus during pregnancy. Smoking is highly addictive due to the nicotine content, which makes quitting smoking a significant challenge for many individuals.